Clinical pharmacokinetics of imipramine and desipramine
- PMID: 2185906
- DOI: 10.2165/00003088-199018050-00002
Clinical pharmacokinetics of imipramine and desipramine
Abstract
The pharmacokinetics of imipramine and desipramine have been extensively investigated with recent studies designed to understand sources of intersubject variability and to study discrete clinical populations rather than healthy volunteers. Sources of intersubject variability in pharmacokinetics are both genetic (oxidative phenotype) and environmental. Oxidative phenotype has an important impact on first-pass metabolism. In individuals with poor metabolism, systemic availability for imipramine is increased. Intrinsic clearance of desipramine is reduced 4-fold in individuals with poor metabolism. Recent pharmacokinetic studies in diverse patient populations such as the depressed elderly, children and alcoholics have revealed decreased clearance of imipramine in the elderly and increased clearance of both imipramine and desipramine in chronic alcoholics. In at least a third of the population, nonlinear pharmacokinetics of desipramine may be observed at steady-state plasma concentrations above 150 micrograms/L. These nonlinear changes in desipramine pharmacokinetics are not associated with age or sex, but are associated with higher desipramine 2-hydroxydesipramine concentration ratios. Hydroxylated metabolites of imipramine and desipramine may possess both antidepressants and cardiotoxic activity but their formation is rate limited and plasma concentrations tend to follow the parent compound with little accumulation. The potent cardiovascular effects of the hydroxymetabolites may be particularly relevant for the elderly and in acute overdose.
Similar articles
-
Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers.Clin Pharmacol Ther. 1988 May;43(5):509-18. doi: 10.1038/clpt.1988.66. Clin Pharmacol Ther. 1988. PMID: 3365915
-
First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype.Clin Pharmacol Ther. 1988 Apr;43(4):400-6. doi: 10.1038/clpt.1988.50. Clin Pharmacol Ther. 1988. PMID: 3356084
-
Pharmacokinetic correlation between in vitro hepatic microsomal enzyme kinetics and in vivo metabolism of imipramine and desipramine in rats.J Pharm Sci. 1990 Apr;79(4):281-7. doi: 10.1002/jps.2600790402. J Pharm Sci. 1990. PMID: 2352136
-
Imipramine: a model substance in pharmacokinetic research.Acta Psychiatr Scand Suppl. 1988;345:81-4. doi: 10.1111/j.1600-0447.1988.tb08572.x. Acta Psychiatr Scand Suppl. 1988. PMID: 3067542 Review.
-
Death of two subjects due to imipramine and desipramine metabolite accumulation during chronic therapy: a review of the literature and possible mechanisms.J Forensic Sci. 1997 Mar;42(2):335-9. J Forensic Sci. 1997. PMID: 9068197 Review.
Cited by
-
Longitudinal Evaluation of the Effect of Tricyclic Antidepressants and Neuroleptics on the Course of Huntington's Disease-Data from a Real World Cohort.Brain Sci. 2021 Mar 25;11(4):413. doi: 10.3390/brainsci11040413. Brain Sci. 2021. PMID: 33805940 Free PMC article.
-
Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline- and methoxamine-evoked constriction of the dorsal hand vein.Br J Clin Pharmacol. 1999 Sep;48(3):345-54. doi: 10.1046/j.1365-2125.1999.00031.x. Br J Clin Pharmacol. 1999. PMID: 10510145 Free PMC article. Clinical Trial.
-
Clinical pharmacokinetics of clomipramine.Clin Pharmacokinet. 1991 Jun;20(6):447-62. doi: 10.2165/00003088-199120060-00002. Clin Pharmacokinet. 1991. PMID: 2044329 Review.
-
Correlating partitioning and caco-2 cell permeability of structurally diverse small molecular weight compounds.Pharm Res. 1998 Sep;15(9):1490-4. doi: 10.1023/a:1011930411574. Pharm Res. 1998. PMID: 9755906 No abstract available.
-
The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol.Eur J Drug Metab Pharmacokinet. 2014 Mar;39(1):43-52. doi: 10.1007/s13318-013-0133-1. Epub 2013 Jun 1. Eur J Drug Metab Pharmacokinet. 2014. PMID: 23728524 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources